secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001171843-22-005458
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus prioritizes CPI-818; pauses mupadolimab Phase 2; Q2 net loss $8.4M
-------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $56.7M as of June 30, 2022, down from $69.5M at Dec 31, 2021.
- Net loss $8.4M for Q2 2022 vs $11.8M for Q2 2021; R&D expenses fell to $4.9M from $9.1M.
- CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR ongoing; no DLTs up to 600 mg.
- Pausing start of randomized Phase 2 trial of mupadolimab in front-line NSCLC to focus on CPI-818 and conserve capital.
- Expects cash runway into early 2024; full year 2022 net cash use $27-29M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322005458/0001171843-22-005458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184322005458/f8k_080822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-005458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer